Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 7/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 6/20 | 0.32 |
| ▸ | DRD3 | P35462 | 4/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454008 | 0.90 | MAPT (0.44) | MAPTDRD2HTR1ADRD4DRD3 | |
| SCHEMBL5451961 | 0.90 | AR (0.37) | MAPTSLC16A3SLC16A1DRD2HTR1A | |
| SCHEMBL13902765 | 0.83 | ABCB1 (0.46) | MAPTHSP90AB1 | |
| SCHEMBL5467538 | 0.80 | KDM1A (0.35) | SLC16A3SLC16A1KDM1A | |
| SCHEMBL3897793 | 0.78 | CTSA (0.33) | CXCR1 | |
| SCHEMBL3910471 | 0.78 | CTSA (0.33) | CXCR1 | |
| SCHEMBL3897797 | 0.78 | CTSA (0.33) | CXCR1 | |
| SCHEMBL5471697 | 0.76 | DRD2 (0.49) | DRD2HTR1AHTR2ADRD3HTR2C | |
| SCHEMBL6070234 | 0.74 | DRD2 (0.45) | DRD2HTR1AHTR2ADRD4DRD3 | |
| SCHEMBL5469975 | 0.74 | HTR7 (0.49) | MAPTHTR1AHSP90AB1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | MAPT 391/4885SLC16A3 2365/4885SLC16A1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.